Innovator. Advocate.
Together with patients, on a mission to advance transformative treatments for people living with serious and rare diseases.
Problem Solver. Partner.
Working with healthcare providers, on a mission to advance transformative treatments for people living with serious and rare diseases.
Innovator. Advocate.
Together with patients, on a mission to advance transformative treatments for people living with serious and rare diseases.

Innovator. Advocate.Together with patients, on a mission to advance transformative treatments for people living with serious and rare diseases.

Our Commitment

At Akcea, we’re on a mission to transform the treatment of unaddressed or under-addressed serious and rare diseases with leading-edge, RNA-targeted medicines. Whether you’re a patient living with a serious condition, or a physician whose patient desperately needs a therapy, we know you’re counting on us, and it fuels our unwavering commitment to be a partner to the community through innovation.

Our Programs

Cardiometabolic Lipid Disorders

These disorders are complex, with a multitude of risk factors related to many diseases, rare and relatively common, including pancreatitis, diabetes, liver disease, and multiple forms of cardiovascular disease.

Hereditary Transthyretin (TTR) Amyloidosis

TTR amyloidosis (ATTR) is a rare, progressive and fatal genetic disease that currently only has limited treatment options that do not treat the underlying cause of disease.

More about Our Programs

Learning about hereditary transthyretin (TTR) amyloidosis

TTR amyloidosis (ATTR) is a rare, progressive and fatal genetic disease that currently only has limited treatment options that do not treat the underlying cause of disease.

Visit hattrchangethecourse.com

Learning about familial chylomicronemia syndrome (FCS)

FCS is a severe and rare disease caused by an enzyme deficiency that leads to the buildup of chylomicrons and a high risk of life-threatening pancreatitis

Visit FCSFocus.com